ILIAS: Ilias Biologics Raises $20.6M in Series B Financing

Ilias Biologics Inc. (previously Cellex Life Sciences, Inc.), a Daejeon, South Korea-based exosome-based therapeutics company, completed a Series B financing round of $20.6m. The initial investors from the Series A round, HB Investment, Timefolio Asset Management, and Daedeok Venture Partners joined this round with follow-on investment. The new institutional investors, including Asset One, Devsisters Ventures, Meritz [...] The post Ilias Biologics Raises $20.6M in Series B Financing appeared first on FinSMEs.